Aurobindo Pharma’s group entity, has entered into an arrangement with Viatris Inc. for an aggregate value of $48 million in relation to transfer from Viatris Inc. of certain marketing and manufacturing related authorisations which will be subject to approval from applicable regulatory authorities and third parties. The arrangement also contemplates participation in the supply system in relation to certain marketing and manufacturing related authorisations and sharing of the net economic benefits by Viatris Inc. to such group entity of the Company.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
